Conference Coverage

Rivaroxaban bonus: Early unmasking of occult GI cancers

Publish date: September 22, 2018

 

REPORTING FROM THE ESC CONGRESS 2018

Pages

Recommended Reading

Rivaroxaban superior to aspirin for extended VTE treatment
MDedge Hematology and Oncology
New stroke intervention guidelines stress volume
MDedge Hematology and Oncology
Think DEB, not BMS, with high bleeding risk
MDedge Hematology and Oncology
EC approves product for von Willebrand disease
MDedge Hematology and Oncology
Hemophilia B drug available in larger vial
MDedge Hematology and Oncology
Caplacizumab approved to treat aTTP
MDedge Hematology and Oncology
Rivaroxaban has ‘favorable’ benefit-risk profile
MDedge Hematology and Oncology
A new standard of care in hemophilia A?
MDedge Hematology and Oncology
Factor VIII product approved for hemophilia A
MDedge Hematology and Oncology
Rivaroxaban doesn’t reduce risk of fatal VTE
MDedge Hematology and Oncology